| I-15 Alan Faraj Model-informed dose selection in phase-3 trials for prophylactic treatment with dalcinonacog alfa in adult and pediatric hemophilia B patients Wednesday 09:45-11:15 |
| I-16 Alan Faraj A joint ketamine and esketamine exposure-response model of MADRS score in major depressive disorder to enable informed trial design for candidate drugs with similar mode of action Wednesday 09:45-11:15 |
